176 related articles for article (PubMed ID: 33473345)
1. Quantitative whole-body magnetic resonance imaging in children with Pompe disease: Clinical tools to evaluate severity of muscle disease.
Fernandes SA; Khan AA; Boggs T; Bowling M; Austin S; Stefanescu M; Case L; Kishnani PS
JIMD Rep; 2021 Jan; 57(1):94-101. PubMed ID: 33473345
[TBL] [Abstract][Full Text] [Related]
2. Whole-body magnetic resonance imaging in late-onset Pompe disease: Clinical utility and correlation with functional measures.
Khan AA; Boggs T; Bowling M; Austin S; Stefanescu M; Case L; Kishnani PS
J Inherit Metab Dis; 2020 May; 43(3):549-557. PubMed ID: 31710733
[TBL] [Abstract][Full Text] [Related]
3. Physical therapy assessment and whole-body magnetic resonance imaging findings in children with glycogen storage disease type IIIa: A clinical study and review of the literature.
Paschall A; Khan AA; Enam SF; Boggs T; Hijazi G; Bowling M; Austin S; Case LE; Kishnani P
Mol Genet Metab; 2021 Nov; 134(3):223-234. PubMed ID: 34649782
[TBL] [Abstract][Full Text] [Related]
4. Newborn screening for Pompe disease in Italy: Long-term results and future challenges.
Gragnaniello V; Pijnappel PWWM; Burlina AP; In 't Groen SLM; Gueraldi D; Cazzorla C; Maines E; Polo G; Salviati L; Di Salvo G; Burlina AB
Mol Genet Metab Rep; 2022 Dec; 33():100929. PubMed ID: 36310651
[TBL] [Abstract][Full Text] [Related]
5. Correlation between quantitative whole-body muscle magnetic resonance imaging and clinical muscle weakness in Pompe disease.
Horvath JJ; Austin SL; Case LE; Greene KB; Jones HN; Soher BJ; Kishnani PS; Bashir MR
Muscle Nerve; 2015 May; 51(5):722-30. PubMed ID: 25155446
[TBL] [Abstract][Full Text] [Related]
6. Muscle ultrasound in patients with late-onset Pompe disease identified by newborn screening.
Jackson DG; Case LE; Huggins E; Holland M; Blount J; Webb LH; Kishnani PS
Mol Genet Metab Rep; 2023 Sep; 36():100989. PubMed ID: 37670900
[TBL] [Abstract][Full Text] [Related]
7. Validation of the Patient-Reported Outcomes Measurement Information System (PROMIS
Kishnani PS; Shohet S; Raza S; Hummel N; Castelli JP; Sitaraman Das S; Jiang H; Kopiec A; Keyzor I; Hahn A
J Patient Rep Outcomes; 2024 Jan; 8(1):13. PubMed ID: 38294575
[TBL] [Abstract][Full Text] [Related]
8. White matter lesions in treated late onset Pompe disease are not different to matched controls.
Schneider I; Hensel O; Zierz S
Mol Genet Metab; 2019 Jun; 127(2):128-131. PubMed ID: 31153821
[TBL] [Abstract][Full Text] [Related]
9. Higher dosing of alglucosidase alfa improves outcomes in children with Pompe disease: a clinical study and review of the literature.
Khan AA; Case LE; Herbert M; DeArmey S; Jones H; Crisp K; Zimmerman K; ElMallah MK; Young SP; Kishnani PS
Genet Med; 2020 May; 22(5):898-907. PubMed ID: 31904026
[TBL] [Abstract][Full Text] [Related]
10. Baseline Urinary Glucose Tetrasaccharide Concentrations in Patients with Infantile- and Late-Onset Pompe Disease Identified by Newborn Screening.
Chien YH; Goldstein JL; Hwu WL; Smith PB; Lee NC; Chiang SC; Tolun AA; Zhang H; Vaisnins AE; Millington DS; Kishnani PS; Young SP
JIMD Rep; 2015; 19():67-73. PubMed ID: 25681082
[TBL] [Abstract][Full Text] [Related]
11. Muscle imaging data in late-onset Pompe disease reveal a correlation between the pre-existing degree of lipomatous muscle alterations and the efficacy of long-term enzyme replacement therapy.
Gruhn KM; Heyer CM; Güttsches AK; Rehmann R; Nicolas V; Schmidt-Wilcke T; Tegenthoff M; Vorgerd M; Kley RA
Mol Genet Metab Rep; 2015 Jun; 3():58-64. PubMed ID: 26937398
[TBL] [Abstract][Full Text] [Related]
12. Regional variation of thigh muscle fat infiltration in patients with neuromuscular diseases compared to healthy controls.
Greve T; Burian E; Zoffl A; Feuerriegel G; Schlaeger S; Dieckmeyer M; Sollmann N; Klupp E; Weidlich D; Inhuber S; Löffler M; Montagnese F; Deschauer M; Schoser B; Bublitz S; Zimmer C; Karampinos DC; Kirschke JS; Baum T
Quant Imaging Med Surg; 2021 Jun; 11(6):2610-2621. PubMed ID: 34079727
[TBL] [Abstract][Full Text] [Related]
13. Prospective exploratory muscle biopsy, imaging, and functional assessment in patients with late-onset Pompe disease treated with alglucosidase alfa: The EMBASSY Study.
van der Ploeg A; Carlier PG; Carlier RY; Kissel JT; Schoser B; Wenninger S; Pestronk A; Barohn RJ; Dimachkie MM; Goker-Alpan O; Mozaffar T; Pena LD; Simmons Z; Straub V; Guglieri M; Young P; Boentert M; Baudin PY; Wens S; Shafi R; Bjartmar C; Thurberg BL
Mol Genet Metab; 2016 Sep; 119(1-2):115-23. PubMed ID: 27473031
[TBL] [Abstract][Full Text] [Related]
14. Real-world outcomes from a series of patients with late onset Pompe disease who switched from alglucosidase alfa to avalglucosidase alfa.
Carter C; Boggs T; Case LE; Kishnani P
Front Genet; 2024; 15():1309146. PubMed ID: 38313679
[No Abstract] [Full Text] [Related]
15. Quantitative Muscle MRI in Patients with Neuromuscular Diseases-Association of Muscle Proton Density Fat Fraction with Semi-Quantitative Grading of Fatty Infiltration and Muscle Strength at the Thigh Region.
Schlaeger S; Sollmann N; Zoffl A; Becherucci EA; Weidlich D; Kottmaier E; Riederer I; Greve T; Montagnese F; Deschauer M; Schoser B; Zimmer C; Karampinos DC; Kirschke JS; Baum T
Diagnostics (Basel); 2021 Jun; 11(6):. PubMed ID: 34201303
[TBL] [Abstract][Full Text] [Related]
16. The impact of antibodies in late-onset Pompe disease: a case series and literature review.
Patel TT; Banugaria SG; Case LE; Wenninger S; Schoser B; Kishnani PS
Mol Genet Metab; 2012 Jul; 106(3):301-9. PubMed ID: 22613277
[TBL] [Abstract][Full Text] [Related]
17. Insight into the phenotype of infants with Pompe disease identified by newborn screening with the common c.-32-13T>G "late-onset" GAA variant.
Rairikar MV; Case LE; Bailey LA; Kazi ZB; Desai AK; Berrier KL; Coats J; Gandy R; Quinones R; Kishnani PS
Mol Genet Metab; 2017 Nov; 122(3):99-107. PubMed ID: 28951071
[TBL] [Abstract][Full Text] [Related]
18. The influence of a polymorphism in the gene encoding angiotensin converting enzyme (ACE) on treatment outcomes in late-onset Pompe patients receiving alglucosidase alfa.
Baek RC; Palmer R; Pomponio RJ; Lu Y; Ma X; McVie-Wylie AJ
Mol Genet Metab Rep; 2016 Sep; 8():48-50. PubMed ID: 27489778
[TBL] [Abstract][Full Text] [Related]
19. Follow-up of late-onset Pompe disease patients with muscle magnetic resonance imaging reveals increase in fat replacement in skeletal muscles.
Nuñez-Peralta C; Alonso-Pérez J; Llauger J; Segovia S; Montesinos P; Belmonte I; Pedrosa I; Montiel E; Alonso-Jiménez A; Sánchez-González J; Martínez-Noguera A; Illa I; Díaz-Manera J
J Cachexia Sarcopenia Muscle; 2020 Aug; 11(4):1032-1046. PubMed ID: 32129012
[TBL] [Abstract][Full Text] [Related]
20. Albuterol as an adjunctive treatment to enzyme replacement therapy in infantile-onset Pompe disease.
Chien YH; Hwu WL; Lee NC; Tsai FJ; Koeberl DD; Tsai WH; Chiu PC; Chang CL
Mol Genet Metab Rep; 2017 Jun; 11():31-35. PubMed ID: 28480166
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
